TFFP: TFF Pharmaceuticals Inc. Forecast Levels Chart

Corporate company logo of TFF Pharmaceuticals Inc. (TFFP)

TFF Pharmaceuticals (TFFP) management is transparently settling obligations and liquidating intellectual property due to a funding shortage, as confirmed by SEC filings. The complete departure of employees has erased internal scientific potential, and the current consensus on the price chart stands at 29.86. The business relies on owning patents for powder inhalations, which generate perpetual royalties from pharmaceutical behemoths.

TFF Pharmaceuticals, Inc (TFFP) - Price Target Chart from 07/04/2022 to 12/21/2024
Flagship merchandise of TFF Pharmaceuticals, Inc

The indicator is calculated by weighting market capitalization against the actual scale of the business, determining the company's ability to offset cost inflation and wage growth without compromising fundamental stability. For TFF Pharmaceuticals, which attracts leading scientists in the field of drug delivery systems, the average projected price from investment banks reflects the market's valuation of the commercialization efficiency of its unique innovative formula freezing technologies.

Competitors of TFF Pharmaceuticals

Analyst Forecast Prices HLN|Analyst Consensus Forecast KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Forecast Levels Chart|Jyong Biotech Corp - Analyst Consensus Forecast|Forecast Levels Chart LGND|Amneal Pharmaceuticals (AMRX) - Price Target Chart|Forecast Levels Chart PRGO (perrigo.com)|Price Target Chart Alvotech SA|Liquidia Corp - Forecast Levels Chart|Analyst Consensus Forecast GLPG|ANIP (ANI Pharmaceuticals Corp) - Fair Value Consensus|Analyst Consensus Forecast MNKD (MannKind Corporation)|Analyst Consensus Forecast amphastar.com AMPH|PCRX - Price Target Chart|Fair Value Consensus SPRY (ARS Pharmaceuticals Inc)|Theravance (TBPH) - Price Target Chart|Consensus Target Aquestive Corp|SCPH (scPharmaceuticals, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Tectonic|Consensus Target TNXP (Tonix Pharmaceuticals Holding Corp.)|SXTC (sxtchina.com) - Fair Value Consensus|Price Target Chart Eupraxia Pharmaceuticals Inc. EPRX|BioHarvest Sciences Inc (BHST) - Average Forecast Price|EXOZ: Consensus Target|Oramed Pharmaceuticals - Analyst Forecast Prices|ENTX: Analyst Consensus Forecast|MindWalk Holdings, Inc. - Fair Value Consensus|ABVC (ABVC BioPharma Inc) - Analyst Consensus Forecast|Average Forecast Price Cumberland Corp CPIX|Price Target Chart Quantum BioPharma Ltd (QNTM)|FGEN (fibrogen.com) - Fair Value Consensus|Telomir Pharmaceuticals, Inc. - Consensus Target|Analyst Forecast Prices RANI (Rani Therapeutics Holdings)|Synergy CHC Corporation - Analyst Consensus Forecast|Forecast Levels Chart RLYB|LEXX: Analyst Consensus Forecast|Forecast Levels Chart PULM (pulmatrix.com)|Consensus Target PTHL|APM: Fair Value Consensus|Price Target Chart Lyra Therapeutics, Inc (LYRA)|IBO: Forecast Levels Chart|Analyst Consensus Forecast TNFA (TNF Pharmaceuticals, Inc.)|Fair Value Consensus YCBD|PainReform - Analyst Consensus Forecast|CYTO - Analyst Consensus Forecast|Lipella (LIPO) - Price Target Chart|OptiNose Corp - Fair Value Consensus|Price Target Chart Pieris Pharmaceuticals|Consensus Target procapsgroup.com (PROC)|Analyst Consensus Forecast PTPI|Analyst Consensus Forecast Qilian International Holding Group (QLI)|Analyst Consensus Forecast SLRN (ACELYRIN, Inc.)